# Gain Therapeutics, Inc.: financial statements, quarterly

GANX · Nasdaq · CIK 1819411 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ganx.md) · [Financials](/companies/ganx/financials.md) · [Filings](/companies/ganx/filings.md) · [Insiders](/companies/ganx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ganx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [0.0 d](/filings/0001558370-24-015709.md) | [0.0 d](/filings/0001558370-25-003823.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $k | [2,367](/filings/0001558370-24-015709.md) | [2,374 d](/filings/0001558370-25-003823.md) | [2,507](/filings/0001558370-25-007747.md) | [4,438](/filings/0001558370-25-011220.md) | [2,622](/filings/0001104659-25-110347.md) | [1,225 d](/filings/0001104659-26-035188.md) | [2,257](/filings/0001104659-26-058649.md) | [2,759](/filings/0001104659-26-094048.md) | [2,850](/filings/0001104659-25-110347.md) | [2,347 d](/filings/0001104659-26-035188.md) | [2,763](/filings/0001104659-26-058649.md) | [2,138](/filings/0001104659-26-094048.md) |
| Operating income | $k | [(4,885)](/filings/0001558370-24-015709.md) | [(4,407) d](/filings/0001558370-25-003823.md) | [(4,378)](/filings/0001558370-25-007747.md) | [(8,183)](/filings/0001558370-25-011220.md) | [(4,459)](/filings/0001104659-25-110347.md) | [(3,331) d](/filings/0001104659-26-035188.md) | [(4,369)](/filings/0001104659-26-058649.md) | [(5,090)](/filings/0001104659-26-094048.md) | [(4,786)](/filings/0001104659-25-110347.md) | [(4,466) d](/filings/0001104659-26-035188.md) | [(5,354)](/filings/0001104659-26-058649.md) | [(4,682)](/filings/0001104659-26-094048.md) |
| Income tax | $k | [21.5](/filings/0001558370-24-015709.md) | [14.5 d](/filings/0001558370-25-003823.md) | [19.9](/filings/0001558370-25-007747.md) | [1.2](/filings/0001558370-25-011220.md) | [11.0](/filings/0001104659-25-110347.md) | [505 d](/filings/0001104659-26-035188.md) | [101](/filings/0001104659-26-058649.md) | [141](/filings/0001104659-26-094048.md) | [549](/filings/0001104659-25-110347.md) | [70.1 d](/filings/0001104659-26-035188.md) | [183](/filings/0001104659-26-058649.md) | [104](/filings/0001104659-26-094048.md) |
| Net income | $k | [(4,718)](/filings/0001558370-24-015709.md) | [(4,724) d](/filings/0001558370-25-003823.md) | [(4,014)](/filings/0001558370-25-007747.md) | [(8,143)](/filings/0001558370-25-011220.md) | [(4,486)](/filings/0001104659-25-110347.md) | [(3,768) d](/filings/0001104659-26-035188.md) | [(4,530)](/filings/0001104659-26-058649.md) | [(5,809)](/filings/0001104659-26-094048.md) | [(5,284)](/filings/0001104659-25-110347.md) | [(4,538) d](/filings/0001104659-26-035188.md) | [(5,609)](/filings/0001104659-26-058649.md) | [(4,676)](/filings/0001104659-26-094048.md) |
| Diluted EPS | $ per share | [(0.37)](/filings/0001558370-24-015709.md) | not reported | [(0.22)](/filings/0001558370-25-007747.md) | [(0.42)](/filings/0001558370-25-011220.md) | [(0.17)](/filings/0001104659-25-110347.md) | not reported | [(0.16)](/filings/0001104659-26-058649.md) | [(0.19)](/filings/0001104659-26-094048.md) | [(0.15)](/filings/0001104659-25-110347.md) | not reported | [(0.13)](/filings/0001104659-26-058649.md) | [(0.11)](/filings/0001104659-26-094048.md) |
| Basic EPS | $ per share | [(0.37)](/filings/0001558370-24-015709.md) | not reported | [(0.22)](/filings/0001558370-25-007747.md) | [(0.42)](/filings/0001558370-25-011220.md) | [(0.17)](/filings/0001104659-25-110347.md) | not reported | [(0.16)](/filings/0001104659-26-058649.md) | [(0.19)](/filings/0001104659-26-094048.md) | [(0.15)](/filings/0001104659-25-110347.md) | not reported | [(0.13)](/filings/0001104659-26-058649.md) | [(0.11)](/filings/0001104659-26-094048.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [4.3](/filings/0001558370-23-019014.md) | [11.8](/filings/0001558370-25-003823.md) | [10.6](/filings/0001558370-24-008132.md) | [16.9](/filings/0001558370-24-011589.md) | [12.0](/filings/0001558370-24-015709.md) | [10.4](/filings/0001104659-26-035188.md) | [9.1](/filings/0001558370-25-007747.md) | [6.7](/filings/0001558370-25-011220.md) | [8.8](/filings/0001104659-25-110347.md) | [20.8](/filings/0001104659-26-094048.md) | [16.5](/filings/0001104659-26-058649.md) | [13.1](/filings/0001104659-26-094048.md) |
| Current assets | $m | [13.2](/filings/0001558370-23-019014.md) | [17.8](/filings/0001558370-25-003823.md) | [13.9](/filings/0001558370-24-008132.md) | [18.5](/filings/0001558370-24-011589.md) | [13.7](/filings/0001558370-24-015709.md) | [11.6](/filings/0001104659-26-035188.md) | [11.2](/filings/0001558370-25-007747.md) | [9.3](/filings/0001558370-25-011220.md) | [10.5](/filings/0001104659-25-110347.md) | [22.2](/filings/0001104659-26-094048.md) | [18.2](/filings/0001104659-26-058649.md) | [15.0](/filings/0001104659-26-094048.md) |
| Total assets | $m | [14.1](/filings/0001558370-23-019014.md) | [18.6](/filings/0001558370-25-003823.md) | [14.6](/filings/0001558370-24-008132.md) | [19.2](/filings/0001558370-24-011589.md) | [14.4](/filings/0001558370-24-015709.md) | [12.1](/filings/0001104659-26-035188.md) | [11.6](/filings/0001558370-25-007747.md) | [9.8](/filings/0001558370-25-011220.md) | [11.0](/filings/0001104659-25-110347.md) | [22.8](/filings/0001104659-26-094048.md) | [18.7](/filings/0001104659-26-058649.md) | [15.4](/filings/0001104659-26-094048.md) |
| Current liabilities | $m | [5.8](/filings/0001558370-23-019014.md) | [4.9](/filings/0001558370-25-003823.md) | [5.0](/filings/0001558370-24-008132.md) | [6.5](/filings/0001558370-24-011589.md) | [4.6](/filings/0001558370-24-015709.md) | [3.9](/filings/0001104659-26-035188.md) | [5.0](/filings/0001558370-25-007747.md) | [5.2](/filings/0001558370-25-011220.md) | [4.2](/filings/0001104659-25-110347.md) | [3.4](/filings/0001104659-26-094048.md) | [3.9](/filings/0001104659-26-058649.md) | [3.4](/filings/0001104659-26-094048.md) |
| Total liabilities | $m | [6.8](/filings/0001558370-23-019014.md) | [6.0](/filings/0001558370-25-003823.md) | [5.9](/filings/0001558370-24-008132.md) | [7.4](/filings/0001558370-24-011589.md) | [5.5](/filings/0001558370-24-015709.md) | [4.8](/filings/0001104659-26-035188.md) | [5.8](/filings/0001558370-25-007747.md) | [6.1](/filings/0001558370-25-011220.md) | [5.1](/filings/0001104659-25-110347.md) | [4.3](/filings/0001104659-26-094048.md) | [4.7](/filings/0001104659-26-058649.md) | [4.1](/filings/0001104659-26-094048.md) |
| Long-term debt | $m | [0.4](/filings/0001558370-23-019014.md) | [0.4](/filings/0001558370-25-003823.md) | [0.4](/filings/0001558370-24-008132.md) | [0.4](/filings/0001558370-24-011589.md) | [0.4](/filings/0001558370-24-015709.md) | [0.3](/filings/0001104659-26-035188.md) | [0.3](/filings/0001558370-25-007747.md) | [0.3](/filings/0001558370-25-011220.md) | [0.3](/filings/0001104659-25-110347.md) | [0.3](/filings/0001104659-26-094048.md) | [0.3](/filings/0001104659-26-058649.md) | [0.2](/filings/0001104659-26-094048.md) |
| Current portion of debt | $m | [0.1](/filings/0001558370-23-019014.md) | [0.1](/filings/0001558370-25-003823.md) | [0.1](/filings/0001558370-24-008132.md) | [0.1](/filings/0001558370-24-011589.md) | [0.1](/filings/0001558370-24-015709.md) | [0.1](/filings/0001104659-26-035188.md) | [0.1](/filings/0001558370-25-007747.md) | [0.1](/filings/0001558370-25-011220.md) | [0.1](/filings/0001104659-25-110347.md) | [0.1](/filings/0001104659-26-094048.md) | [0.1](/filings/0001104659-26-058649.md) | [0.1](/filings/0001104659-26-094048.md) |
| Shareholders' equity | $m | [7.3](/filings/0001558370-24-015709.md) | [12.6](/filings/0001104659-26-035188.md) | [8.6](/filings/0001558370-25-011220.md) | [11.8](/filings/0001104659-25-110347.md) | [8.9](/filings/0001104659-25-110347.md) | [7.3](/filings/0001104659-26-094048.md) | [5.8](/filings/0001104659-26-094048.md) | [3.7](/filings/0001104659-26-094048.md) | [5.9](/filings/0001104659-25-110347.md) | [18.6](/filings/0001104659-26-094048.md) | [14.0](/filings/0001104659-26-094048.md) | [11.3](/filings/0001104659-26-094048.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(3,967) d](/filings/0001558370-24-015709.md) | [(5,660) d](/filings/0001558370-25-003823.md) | [(3,587)](/filings/0001558370-25-007747.md) | [(5,756) d](/filings/0001558370-25-011220.md) | [(6,076) d](/filings/0001104659-25-110347.md) | [(3,455) d](/filings/0001104659-26-035188.md) | [(3,822)](/filings/0001104659-26-058649.md) | [(5,099) d](/filings/0001104659-26-094048.md) | [(4,926) d](/filings/0001104659-25-110347.md) | [(4,618) d](/filings/0001104659-26-035188.md) | [(4,728)](/filings/0001104659-26-058649.md) | [(4,680) d](/filings/0001104659-26-094048.md) |
| Capital expenditure | $k | [0.7 d](/filings/0001558370-24-015709.md) | [0.0 d](/filings/0001558370-25-003823.md) | not reported | not reported | [0.0 d](/filings/0001104659-25-110347.md) | [0.9 d](/filings/0001104659-26-035188.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [11.9](/filings/0001558370-23-019014.md) | [11.9](/filings/0001558370-24-008132.md) | [12.4](/filings/0001558370-24-011589.md) | [12.7](/filings/0001558370-24-015709.md) | [18.0](/filings/0001558370-25-007747.md) | [19.2](/filings/0001558370-25-011220.md) | [26.5](/filings/0001104659-25-110347.md) | [28.7](/filings/0001104659-26-058649.md) | [30.3](/filings/0001104659-26-094048.md) | [35.0](/filings/0001104659-25-110347.md) | [42.2](/filings/0001104659-26-058649.md) | [42.9](/filings/0001104659-26-094048.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 43,643,619 at 2026-07-31, from the cover of the [10-Q filed 2026-08-11](/filings/0001104659-26-094048.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.